Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 13, 2025 -- For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted readmission, wound dehiscence, and hematoma, according to a study published online Dec. 20 in the Annals of Surgery.
Seth Z. Aschen, M.D., from Weill Cornell Medicine in New York City, and colleagues examined the rates of surgical complications and postoperative readmission in patients with diabetes, with and without perioperative prescriptions for GLP-1 RA medications in a retrospective, observational cohort analysis. Patients with type 1 or type 2 diabetes undergoing a surgical procedure between February 2020 and July 2023 were included.
Overall, 27.2 percent of the 74,425 surgical procedures in 21,772 patients included in the analysis were performed in the setting of an active GLP-1 RA prescription. A total of 35,020 procedures performed in 13,129 patients were propensity score-matched. The researchers found that the active GLP-1 RA prescription group had a significantly lower risk for 30-day readmission and 180-day postoperative wound dehiscence and postoperative hematoma after matching (relative risks, 0.883, 0.711, and 0.440, respectively). The rates of infection and bleeding did not differ significantly.
"With the rapidly increasing prevalence of GLP-1 RA use in patients with and without a diagnosis of diabetes, an understanding of its effect on postoperative complications is critical," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
FRIDAY, July 18, 2025 -- Neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab offers long-term benefit in adults with stage III/IV...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.